Piers currently consults part-time for CellCentric, joining full time before the end of 2021.
Piers is a highly experienced biotech finance leader, having raised almost $1.5bn in new equity, convertibles, venture debt and corporate investments. He has led Nasdaq IPOs for uniQure (QURE), Verona (VRNA) and Compass Pathways (CMPS). He also has experience on both London’s Main Market and AIM, as well as Euronext Paris and Euronext Amsterdam. Piers also managed the trade sale of Quethera to Astellas.
Piers gained an MA in Law and Management Studies from Cambridge University. He went on to qualify as a Chartered Accountant in PwC’s London office before spending almost 10 years as an investment banker focusing on Mergers, Acquisitions and Financings, initially at Close Brothers and later in Ernst & Young’s Lead Advisory practice. He moved into biotech executive management in 2000.